These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25972499)

  • 1. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.
    Ford N; Shubber Z; Calmy A; Irvine C; Rapparini C; Ajose O; Beanland RL; Vitoria M; Doherty M; Mayer KH
    Clin Infect Dis; 2015 Jun; 60 Suppl 3():S170-6. PubMed ID: 25972499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
    Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
    N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
    Penazzato M; Dominguez K; Cotton M; Barlow-Mosha L; Ford N
    Clin Infect Dis; 2015 Jun; 60 Suppl 3():S177-81. PubMed ID: 25972500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
    Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ
    J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Petlo C; Lockman S; Makhema J; Shapiro RL
    JAMA Pediatr; 2017 Oct; 171(10):e172222. PubMed ID: 28783807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
    Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
    BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.
    Campbell TB; Smeaton LM; Kumarasamy N; Flanigan T; Klingman KL; Firnhaber C; Grinsztejn B; Hosseinipour MC; Kumwenda J; Lalloo U; Riviere C; Sanchez J; Melo M; Supparatpinyo K; Tripathy S; Martinez AI; Nair A; Walawander A; Moran L; Chen Y; Snowden W; Rooney JF; Uy J; Schooley RT; De Gruttola V; Hakim JG;
    PLoS Med; 2012; 9(8):e1001290. PubMed ID: 22936892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network meta-analysis.
    Tshivuila-Matala COO; Honeyman S; Nesbitt C; Kirtley S; Kennedy SH; Hemelaar J
    AIDS; 2020 Sep; 34(11):1643-1656. PubMed ID: 32701581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
    Chetty T; Thorne C; Coutsoudis A
    PLoS One; 2018; 13(2):e0192805. PubMed ID: 29470508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
    Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
    HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
    Inciarte A; Leal L; González E; León A; Lucero C; Mallolas J; Torres B; Laguno M; Rojas J; Martínez-Rebollar M; González-Cordón A; Cruceta A; Arnaiz JA; Gatell JM; García F;
    J Antimicrob Chemother; 2017 Oct; 72(10):2857-2861. PubMed ID: 29091217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.
    Kang SJ; An JH; Kim J; Jang MO; Kim SE; Park KH; Jung SI; Jang HC
    Jpn J Infect Dis; 2013; 66(4):317-9. PubMed ID: 23883843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
    Rokx C; Gras L; van de Vijver D; Verbon A; Rijnders B;
    HIV Med; 2016 Sep; 17(8):571-80. PubMed ID: 26842457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, the Immunological Impact, and the Effect on HIV
    Leal L; Guardo AC; Bedoya LM; Rodríguez de Miguel C; Climent N; Rovira C; Beltrán M; Llach J; Alcamí J; Kashuba ADM; Gatell JM; Plana M; García F
    AIDS Res Hum Retroviruses; 2023 May; 39(5):211-221. PubMed ID: 36416229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effects and tolerability of post-exposure prophylaxis with zidovudine, lamivudine, and lopinavir/ritonavir: a comparative study with HIV/AIDS patients.
    Cai J; Xiao J; Zhang Q
    Chin Med J (Engl); 2014; 127(14):2632-6. PubMed ID: 25043080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
    Clumeck N; Mwamba C; Kabeya K; Matanda S; Vaira D; Necsoi C; Kadiebwe D; Delforge M; Kasamba E; Milolo C; Ilunga J; Kapend L
    AIDS; 2014 May; 28(8):1143-53. PubMed ID: 25028911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.
    Luque A; Hulse S; Wang D; Shahzad U; Tanzman E; Antenozzi S; Smith B
    Infect Control Hosp Epidemiol; 2007 Jun; 28(6):695-701. PubMed ID: 17520543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.